HIVManagement.org

 
Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Coreceptor Inhibitors Integrase Inhibitors Drug Summary
Coformulation Antiretroviral Therapy
Investigational Adherence Lab Evaluation Resistance Tests PEP
Antiretroviral Tables OI Prevention Vaccinations TB Therapy Hepatitis Therapy
OI Diagnosis OI Therapy Bibliography Links Palliative Therapy

 

maraviroc

Prescribing Information

 

Direct Links to CCR5 Receptor Blocker Info
Key Points
Generic Brand
maraviroc Selzentry

 

 

Maraviroc = Selzentry

Forms Available 150 and 300 mg tablets
Dosing 150 mg twice daily
With CYP3A inhibitors:
protease inhibitors except for tipranavir/ritonavir
delavirdine
ketoconazole, itraconazole, clarithromycin
other strong CYP3A inhibitors (e.g., nefazadone, telithromycin)
300 mg twice daily
Other concomitant medications, including
tipranavir/ritonavir, nevirapine, all NRTIs and enfuvirtide
600 mg twice daily
With CYP3A inducers (without a strong inhibitor)
efavirenz
rifampin
carbemazepine, phenobarbital, phenytoin
Adverse Effects Maraviroc is an alpha-blocker with some antihypertensive and orthostatic hypotension effects.
Hepatotoxicity is rare, but possibly severe.
Interactions See dosing above
Suggested lab follow-up Tropism assay must be performed prior to prescribing this medication, and the result must indicated the absence of any CXCR4 (X4) virus. 
Routine virologic and safety monitoring should be performed during the administration of this medication.
Warning Hepatotoxicity: if elevated liver enzymes are noted in association with signs or symptoms of hepatitis, rash or other systemic symptoms, discontinuation should be considered
Cardiovascular events:
there is possible association of maraviroc therapy with cardiac ischemia or infarction (1.3% vs none in placebo recipients)
Orthostatic hypotension:  caution should be advised when administering maraviroc to a patient with a history of orthostatic hypotension or to a patient taking antihypertensive medication
Complete prescribing information Full prescribing information

 

 

Next Page

Click HERE for Antiretroviral Therapy Summary and Recommendations

 

 
Links to Antiretroviral Sections
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI)
AZT  |  ddI  |  d4T  |  3TC  |  ABC  |  FTC  |  TDF  ||| Coformulation NRTI:  Combivir  |  Trizivir  |  Epzicom  |  Truvada
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI)
efavirenz  |  nevirapine  |  delavirdine  |  etravirine  |  rilpivirine
Protease Inhibitors (PI)  |  Boosted Protease Inhibitors
saquinavir  indinavir  |  ritonavir  |  nelfinavir  |  lopinavir + ritonavir  |  atazanavir  |  fosamprenavir  | tipranavir
Co-receptor Inhibitors
maraviroc
Fusion Inhibitors
enfuvirtide
Integrase Inhibitors
raltegravir  |  elvitegravir
Antiretroviral Metabolic Inhibitors
cobicistat  |  ritonavir
Coformulations
Atripla (efavirenz/tenofovir/emtricitabine)  |  Complera (rilpivirine/tenofovir/emtricitabine)  | Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine)
 
 
Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Coreceptor Inhibitors Integrase Inhibitors Drug Summary
Coformulation Antiretroviral Therapy
Investigational Adherence Lab Evaluation Resistance Tests PEP
Antiretroviral Tables OI Prevention Vaccinations TB Therapy Hepatitis Therapy
OI Diagnosis OI Therapy Bibliography Links Palliative Therapy

 

Updated 1/14/2013